NEW VACCINES AND DIAGNOSTICS
Together with the Medical University of Vienna, international partners and clinical studies we have developed completely new concepts for preventive and therapeutic vaccines and diagnostics for Hepatitis B, SARS- CoV-2, HIV, RSV and Rhinovirus. We foster innovation and new concepts in order to increase the opportunities to prevent and treat infectious diseases. To maximize our potential we actively seek partners like pharmaceutical companies to accelerate the development and commercialization of our existing pipeline.
On the 3rd of September 2024 the shareholders of Viravaxx AG decided to sell all patents and intellectual properties to interested partners and to dissolve the company. So the company name changed from Viravaxx AG to Viravaxx AG i.A. The addendum i.A. is the German abbreviation for winding – up a company.